Cardio Diagnostics Holdings logo

Cardio Diagnostics HoldingsNASDAQ: CDIO

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

14 January 2022

Next earnings report:

29 November 2024

Last dividends:

N/A

Next dividends:

N/A
$5.17 M
-93%vs. 3y high
13%vs. sector
-vs. 3y high
-vs. sector
-92%vs. 3y high
52%vs. sector
132.27
-99%vs. 3y high
94%vs. sector

Price

after hours | Thu, 24 Oct 2024 23:46:24 GMT
$0.21+$0.00(+1.27%)

Dividend

No data over the past 3 years
$7.90 K$100.00 K
$7.90 K-$1.29 M

Analysts recommendations

Institutional Ownership

CDIO Latest News

Cardio Diagnostics Announces It's Exhibiting at the 2024 Onsite Employee Health Clinics Forum
businesswire.com25 June 2024 Sentiment: POSITIVE

CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics will sponsor a booth and showcase its groundbreaking cardiovascular solutions at the 2024 Onsite Employee Health Clinics Forum.

Cardio Diagnostics Holdings, Inc. Achieves SOC 2 Type I Compliance Certification for Security and Confidentiality
businesswire.com10 June 2024 Sentiment: POSITIVE

CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics today announced the successful completion of its System and Organization Controls (SOC) 2 Type I audit.

Cardio Diagnostics shares rocket on validation of coronary heart disease detection test
Proactive Investors20 November 2023 Sentiment: POSITIVE

Cardio Diagnostics Holdings shares added more than 75% on Monday after positive results from a trial of the company's coronary heart disease (CHD) test PrecisionCHD were published in the Journal of the American Heart Association. The company noted that PrecisionCHD is a non-invasive and more accessible alternative to current CHD diagnosis tools being in the form of a blood test that uses AI and personalized genetic and epigenetic information to sensitively detect the presence of CHD.

Why Is Cardio Diagnostics (CDIO) Stock Up 45% Today?
InvestorPlace31 October 2023 Sentiment: POSITIVE

Shares of cardiovascular medicine specialist Cardio Diagnostics (NASDAQ: CDIO ) are skyrocketing on Tuesday following the announcement of a key deal. Specifically, Vizient has awarded Cardio Diagnostics an “Innovation Technology” contract for its artificial intelligence (AI) driven molecular heart disease tests.

What type of business is Cardio Diagnostics Holdings?

Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.

What sector is Cardio Diagnostics Holdings in?

Cardio Diagnostics Holdings is in the Healthcare sector

What industry is Cardio Diagnostics Holdings in?

Cardio Diagnostics Holdings is in the Biotechnology industry

What country is Cardio Diagnostics Holdings from?

Cardio Diagnostics Holdings is headquartered in United States

When did Cardio Diagnostics Holdings go public?

Cardio Diagnostics Holdings initial public offering (IPO) was on 14 January 2022

What is Cardio Diagnostics Holdings website?

https://cardiodiagnosticsinc.com

Is Cardio Diagnostics Holdings in the S&P 500?

No, Cardio Diagnostics Holdings is not included in the S&P 500 index

Is Cardio Diagnostics Holdings in the NASDAQ 100?

No, Cardio Diagnostics Holdings is not included in the NASDAQ 100 index

Is Cardio Diagnostics Holdings in the Dow Jones?

No, Cardio Diagnostics Holdings is not included in the Dow Jones index

When was Cardio Diagnostics Holdings the previous earnings report?

No data

When does Cardio Diagnostics Holdings earnings report?

The next expected earnings date for Cardio Diagnostics Holdings is 29 November 2024